OGT
Oxford Gene Technology is a genomic diagnostics company developing and manufacturing hybridisation-based reagents and assays for clinical and research laboratories.
Its product portfolio spans FISH probes, chromosomal microarrays and next-generation sequencing panels, enabling detection of chromosomal abnormalities and somatic mutations across haematological malignancies, solid tumours, cytogenetics and rare diseases.
A FISH probe for KMT2A rearrangement in acute leukaemia received FDA De Novo classification as a companion diagnostic in 2024.
Latest News
OGT Adds Four IVDR-Certified CytoCell FISH Probes for Blood Cancers
OGT has expanded its CytoCell portfolio with four fluorescence in situ hybridisation (FISH) probes newly certified under the EU In Vitro Diagnostic Regulation (IVDR). The assays, including ATM and IGH-targeting probes, were already available under the older IVDD framework and support cytogenetic assessment of haematological malignancies. Their certification forms part of OGT's staged transition ahead of the December 2028 Class C deadline.
OGT Launches First Dedicated Fusion MRD NGS Panel for AML
OGT has launched the SureSeq myPanel Myeloid Fusion MRD Panel, which it describes as the first dedicated next-generation sequencing panel for detecting AML fusion events at measurable residual disease sensitivity. The research-use panel was developed with Roswell Park Comprehensive Cancer Center and can be run alongside OGT's Myeloid MRD Plus panel.